Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN: AGTC-501 in XLRP Fellow Eye
NCT06275620Phase 2Enrolling by invitation
- Sponsor
- Beacon Therapeutics
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of laruparetigene zovaparvovec in retinitis pigmentosa (RP), sponsored by Beacon Therapeutics. Started Nov 2023; status: enrolling by invitation.
02
Drugs
laruparetigene zovaparvovec
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06275620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275620.